9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 21

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: maximum tolerated dose of LMB100 +nab-paclitaxel,  maximum tolerated dose of LMB-100,  proportion of patients at MTD with paartial or complete response per RECIST, average time from treatment initiaition to disease progression or death

Interventions: LMB-100, nab-paclitaxel

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: July 20, 2017

Completion Date: August 5, 2020

Last  Posted Date: April 11, 2019

Location: National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT02798536

Was this article helpful?
Dislike 0